Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion type Assertion NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_head.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion evidence source_evidence_literature NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion SIO_000772 15248218 NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion wasDerivedFrom befree-2016 NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.
- NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion wasGeneratedBy ECO_0000203 NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.